Foghorn Therapeutics Business Summary

Foghorn Therapeutics Inc. (FHTX) is a clinical-stage biopharmaceutical company that generates revenue primarily through strategic research collaborations, licensing agreements, and equity financing. The company operates through its proprietary Gene Traffic Control platform, a scalable discovery engine designed to identify and drug targets within the chromatin regulatory system, which is implicated in over 25% of all cancers. Its primary business segments are focused on oncology, with a pipeline featuring lead assets such as FHD-909 (a SMARCA2 inhibitor partnered with Eli Lilly), the selective ATPase inhibitor FHD-286, and a suite of protein degraders targeting CBP, EP300, and ARID1B. Foghorn competes directly with targeted protein degradation and epigenetic specialists such as Kymera Therapeutics, Arvinas, Nurix Therapeutics, and C4 Therapeutics, positioning itself as a first-mover in the high-density chromatin remodeling space to address previously "undruggable" genetic dependencies. Founded in 2016 by Flagship Pioneering, Foghorn was co-conceptualized by Doug Cole, MD, a Managing Partner at Flagship who currently serves as Chairman of the Board. The executive team is led by President and CEO Adrian Gottschalk, who joined in 2017 after a 13-year tenure at Biogen, where he served as Senior Vice President and head of the neurodegeneration therapeutic area. Supporting the technical roadmap are Chief Scientific Officer Steven Bellon, PhD, formerly of Constellation Pharmaceuticals, and Chief Medical Officer Alfonso Quintás-Cardama, MD, who previously led CAR-T development at Novartis. Following a leadership transition in late 2025, Jeff Sacher serves as Treasurer and Interim CFO, while Anna Rivkin, PhD, oversees commercial strategy as Chief Business Officer. The company maintains a strong institutional backing from notable investors including Flagship Pioneering, BVF Partners, and Deerfield Management.